Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study	BLOOD	2015
OUTCOME OF AZACITIDINE TREATMENT AND INCIDENCE OF FEBRILE EVENTS IN "REAL WORLD" PATIENTS WITH MDS OR LOW-BLAST COUNT AML	LEUKEMIA RESEARCH	2015
Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis	BLOOD	2015
PROGNOSTIC FACTORS ASSOCIATED TO ACHIEVEMENT OF STABLE MR4.5 IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB	HAEMATOLOGICA	2015
LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY	HAEMATOLOGICA	2015
A RETROSPECTIVE MULTICENTRE COMPARISON OF INTENSIVE CHEMOTHERAPY WITH AZACITIDINE FOR THE FRONT LINE TREATMENT OF ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS	HAEMATOLOGICA	2015
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?	HEMATOLOGICAL ONCOLOGY	2015
DEEP MOLECULAR RESPONSE TO NILOTINIB AS FIRST-LINE TREATMENT OF BCR-ABL plus CHRONIC MYELOID LEUKEMIA	HAEMATOLOGICA	2015
Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline	BLOOD	2015
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet	LEUKEMIA	2015
LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY	HAEMATOLOGICA	2015
Ponatinib in chronic myeloid leukaemia: ready for first-line?	THE LANCET. HAEMATOLOGY	2015
Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients	BLOOD	2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes	LEUKEMIA RESEARCH	2015
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment	BLOOD CANCER JOURNAL	2015
IS HIGH PLATELET COUNT AT DIAGNOSIS OF ESSENTIAL THROMBOCYTHEMIA A PROTECTIVE FACTOR FOR THROMBOSIS?	HAEMATOLOGICA	2015
FLT3-ITD in acute promyelocytic leukemia: Clinical distinct profile but still controversial prognosis	LEUKEMIA RESEARCH	2015
CARDIOVASCULAR EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FIRST-LINE: AN ANALISYS OF THE GIMEMA CML WP	HAEMATOLOGICA	2015
Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib	BLOOD	2015
LONG-TERM OUTCOME TO FIRST-LINE IMATINIB ACCORDING TO 2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA: A GIMEMA CML WP ANALYSIS	HAEMATOLOGICA	2015